These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 26130996)

  • 21. A review of infliximab use in ulcerative colitis.
    Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
    Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of Safety and Efficacy of Tacrolimus versus Infliximab for Active Ulcerative Colitis.
    Takeuchi K; Shimoyama T; Yamamoto T
    Dig Dis; 2018; 36(2):106-112. PubMed ID: 29050007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Infliximab salvage therapy for patients with ulcerative colitis who failed to respond to tacrolimus.
    Tsukamoto H; Tanida S; Mizoshita T; Ozeki K; Ebi M; Shimura T; Mori Y; Kataoka H; Kamiya T; Joh T
    Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):714-8. PubMed ID: 23411870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus.
    Yamamoto S; Nakase H; Matsuura M; Honzawa Y; Masuda S; Inui K; Chiba T
    J Gastroenterol Hepatol; 2010 May; 25(5):886-91. PubMed ID: 20546441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Comparison of Short- and Long-Term Therapeutic Outcomes of Infliximab- versus Tacrolimus-Based Strategies for Steroid-Refractory Ulcerative Colitis.
    Endo K; Onodera M; Shiga H; Kuroha M; Kimura T; Hiramoto K; Kakuta Y; Kinouchi Y; Shimosegawa T
    Gastroenterol Res Pract; 2016; 2016():3162595. PubMed ID: 26904108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcome of tacrolimus and vedolizumab after corticosteroid and anti-TNF failure in paediatric severe colitis.
    Hamel B; Wu M; Hamel EO; Bass DM; Park KT
    BMJ Open Gastroenterol; 2018; 5(1):e000195. PubMed ID: 29527316
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn's disease: a single-center experience.
    Benson A; Barrett T; Sparberg M; Buchman AL
    Inflamm Bowel Dis; 2008 Jan; 14(1):7-12. PubMed ID: 17879277
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclosporine A for induction of remission in severe ulcerative colitis.
    Shibolet O; Regushevskaya E; Brezis M; Soares-Weiser K
    Cochrane Database Syst Rev; 2005 Jan; (1):CD004277. PubMed ID: 15674937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short-Term and Long-Term Outcomes of Infliximab and Tacrolimus Treatment for Moderate to Severe Ulcerative Colitis: Retrospective Observational Study.
    Otsuka T; Ooi M; Tobimatsu K; Wakahara C; Watanabe D; Adachi S; Yasutomi E; Yamairi H; Ku Y; Yoshida M; Hoshi N; Kodama Y
    Kobe J Med Sci; 2018 Dec; 64(4):E140-E148. PubMed ID: 30728340
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tacrolimus induction followed by maintenance monotherapy is useful in selected patients with moderate-to-severe ulcerative colitis refractory to prior treatment.
    Boschetti G; Nancey S; Moussata D; Stefanescu C; Roblin X; Chauvenet M; Stroeymeyt K; Bouhnik Y; Flourié B
    Dig Liver Dis; 2014 Oct; 46(10):875-80. PubMed ID: 25023007
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes and adverse events in children and young adults undergoing tacrolimus therapy for steroid-refractory colitis.
    Watson S; Pensabene L; Mitchell P; Bousvaros A
    Inflamm Bowel Dis; 2011 Jan; 17(1):22-9. PubMed ID: 20722055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medical Therapy of Active Ulcerative Colitis.
    Bürger M; Schmidt C; Teich N; Stallmach A
    Viszeralmedizin; 2015 Aug; 31(4):236-45. PubMed ID: 26557831
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tacrolimus therapy as an alternative to thiopurines for maintaining remission in patients with refractory ulcerative colitis.
    Yamamoto S; Nakase H; Matsuura M; Masuda S; Inui K; Chiba T
    J Clin Gastroenterol; 2011 Jul; 45(6):526-30. PubMed ID: 21336140
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tacrolimus Therapy for Ulcerative Colitis-Associated Post-Colectomy Enteritis.
    Rush B; Berger L; Rosenfeld G; Bressler B
    ACG Case Rep J; 2014 Oct; 2(1):33-5. PubMed ID: 26157899
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclosporine or infliximab as rescue therapy in severe refractory ulcerative colitis: early and long-term data from a retrospective observational study.
    Mocciaro F; Renna S; Orlando A; Rizzuto G; Sinagra E; Orlando E; Cottone M
    J Crohns Colitis; 2012 Jul; 6(6):681-6. PubMed ID: 22398101
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the therapeutic efficacy and safety between tacrolimus and infliximab for moderate-to-severe ulcerative colitis: a single center experience.
    Nuki Y; Esaki M; Asano K; Maehata Y; Umeno J; Moriyama T; Nakamura S; Matsumoto T; Kitazono T
    Scand J Gastroenterol; 2016; 51(6):700-5. PubMed ID: 26818468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis.
    Yamamoto S; Nakase H; Mikami S; Inoue S; Yoshino T; Takeda Y; Kasahara K; Ueno S; Uza N; Kitamura H; Tamaki H; Matsuura M; Inui K; Chiba T
    Aliment Pharmacol Ther; 2008 Sep; 28(5):589-97. PubMed ID: 18549460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease.
    Christensen B; Gibson PR; Micic D; Colman RJ; Goeppinger SR; Kassim O; Yarur A; Weber CR; Cohen RD; Rubin DT
    Clin Gastroenterol Hepatol; 2019 Feb; 17(3):486-493. PubMed ID: 29751166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials.
    Cholapranee A; Hazlewood GS; Kaplan GG; Peyrin-Biroulet L; Ananthakrishnan AN
    Aliment Pharmacol Ther; 2017 May; 45(10):1291-1302. PubMed ID: 28326566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tacrolimus versus anti-tumor necrosis factor agents for steroid-refractory active ulcerative colitis based on the severity of endoscopic findings: a single-center, open-label cohort study.
    Matsumoto S; Kawamura H; Nishikawa T; Sagihara N; Miyatani H; Mashima H
    Clin Exp Gastroenterol; 2017; 10():249-258. PubMed ID: 29026326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.